| Autor: |
Rastin F; Department of Biology, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. farangis.rastiin@gmail.com., Oryani MA; Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Akbarimh1@mums.ac.ir., Iranpour S; Department of Chemistry, Faculty of Science, Ferdowsi University of Mashhad, Mashhad, Iran. Sonia.Iranpour@yahoo.com., Javid H; Department of Medical Laboratory Sciences, Varastegan Institute for Medical Sciences, Mashhad, Iran.; Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Javidh@varastegan.ac.ir.; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hashemzadehalireza@gmail.com., Hashemzadeh A; Department of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Hashemzadehalireza@gmail.com., Karimi-Shahri M; Department of Pathology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran. Akbarimh1@mums.ac.ir.; Department of Pathology, School of Medicine, Gonabad University of Medical Sciences, Gonabad, Iran. |
| Abstrakt: |
This review delves into the potential of zeolitic imidazolate framework-8 (ZIF-8) nanoparticles in augmenting the efficacy of cancer immunotherapy, with a special focus on the delivery of programmed cell death receptor 1 (PD-1) inhibitors. The multifunctional nature of ZIF-8 nanoparticles as drug carriers is emphasized, with their ability to encapsulate a range of therapeutic agents, including PD-1 inhibitors, and facilitate their targeted delivery to tumor locations. By manipulating the pore size and surface characteristics of ZIF-8 nanoparticles, controlled drug release can be realized. The strategic use of ZIF-8 nanoparticles to deliver PD-1 inhibitors presents a precise and targeted modality for cancer treatment, reducing off-target impacts and enhancing therapeutic effectiveness. This combined strategy addresses the existing challenges and constraints of current immunotherapy techniques, with the ultimate goal of enhancing patient outcomes in cancer therapy. |
